Tranylcypromine/trifluoperazine

See also

References

1. ^ Dart RC (2004). "Monoamine Oxidase Inhibitors". Medical Toxicology. Lippincott Williams & Wilkins. pp. 825–. ISBN 978-0-7817-2845-4.
2. ^ Stahl SM (15 May 2014). Prescriber's Guide: Stahl's Essential Psychopharmacology. Cambridge University Press. pp. 783–. ISBN 978-1-107-67502-5.
3. ^ ^{a b c} Straker M, Grauer H (July 1961). "Clinical Study of a Potent Antidepressant, Tranylcypromine with Trifluorperazine (Parstelin ), in the Aged Chronically Ill". Canadian Medical Association Journal. 85 (3): 127–130. PMC 1848140 . PMID 20326829.
4. ^ Kalinowsky LB, Hippius H, Klein HE (1982). Biological Treatments in Psychiatry. Grune and Stratton, Harcourt Brace Jovanovich. ISBN 978-0-8089-1423-5.
5. ^ Cowdry, R. W., & Gardner, D. L. (1988). Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Archives of general psychiatry, 45(2), 111–119. https://doi.org/10.1001/archpsyc.1988.01800260015002